The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca Japan; Stryker
Speakers' Bureau - Eisai
Research Funding - Hitachi Chemical
A multicenter nonrandomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF cohort trial).
 
Ryosuke Tateishi
Honoraria - Abbvie; Bayer Yakuhin; Daiichi Sankyo; Eisai; Fujifilm; GE Healthcare; Gilead Sciences; Merck Sharp & Dohme; Otsuka; Shionogi; Sumitomo Dainippon; Taisho Toyama Pharma
 
Kiyoshi Hasegawa
Honoraria - Bayer Yakuhin; Merck Sharp & Dohme
Research Funding - Shimadzu; Shimadzu
Other Relationship - Abbvie; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Eisai; Eisai; Taiho Pharmaceutical; Takeda
 
Yoshikuni Kawaguchi
Honoraria - Olympus; Otsuka
Consulting or Advisory Role - Conmed
 
Tadatoshi Takayama
No Relationships to Disclose
 
Namiki Izumi
No Relationships to Disclose
 
Naoki Yamanaka
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - Bayer; Eisai; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Mitsuo Shimada
No Relationships to Disclose
 
Masafumi Inomata
No Relationships to Disclose
 
Shuichi Kaneko
Honoraria - Abbvie; ASKA Pharmaceutical; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; EA Pharma; EI Dupont; Eisai; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan Pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD; Mylan; Otsuka; Sumitomo Group; Sysmex; Taiho Pharmaceutical; Taisho Toyama Pharma
Consulting or Advisory Role - Bayer; Hokkoku Bank; Kowa
Research Funding - Abbott Vascular Japan; Abbvie; Alexion Pharmaceuticals; ASKA Pharmaceutical; Astellas Pharma; Bayer; Biotronik International; Boehringer Ingelheim; Boston Scientific; Bristol-Myers Squibb; Central Medical; Daiichi Sankyo; EA Pharma; Eisai; Gilead Sciences; Japan Lifeline; Kataoka; Kiowa Kirin; Kowa; Lilly; Medtronic; Mitsubishi Tanabe Pharma; MSD; Mylan; Nihon Medi-Physics; Nippon Kayaku; Novartis; Novo Nordisk; Ono Yakuhin; Otsuka; Pfizer; Sanofi; Sanwa Kagaku Kenkyusho; Shionogi; St Jude Medical Japan; Sumitomo Group; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda; Teijin Pharma; TERUMO; Tomiki Medical Instruments; Zeon Medical; Zeria Pharmaceutical
 
Kazuhiko Koike
Honoraria - Abbvie; Bayer; Eisai; Gilead Sciences; MSD K.K; Otsuka
Consulting or Advisory Role - Asuka Seiyaku; Otsuka
Speakers' Bureau - Abbvie; Bayer; Eisai; Gilead Sciences; MSD; Otsuka
Research Funding - Abbvie; Astellas Pharma; Bayer; EA Pharma; Eisai; Gilead Sciences; MSD; Otsuka; Shionogi; Takeda; Takeda
 
Masao Omata
Honoraria - Abbvie; Eisai; Gilead Sciences; Mitsubishi Tanabe Pharma; MSD; Takeda
 
Masatoshi Makuuchi
No Relationships to Disclose
 
Yutaka Matsuyama
No Relationships to Disclose
 
Norihiro Kokudo
No Relationships to Disclose